Stock RLFTY RELIEF THERAPEUTICS HOLDING SA
Add to a list
To use this feature you must be a member
Log inSign up

Financials Relief Therapeutics Holding SA OTC Markets

Equities

RLFTY

US7595JP3044

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 03:46:12 2024-04-02 pm EDT 		5-day change 1st Jan Change
1.401 USD -2.06% Intraday chart for Relief Therapeutics Holding SA -.--% -33.30%
Apr. 30 Relief Therapeutics Holding SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Apr. 30 Relief Therapeutics' FY23 Loss Widens; Revenue Edges Down MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 10.86 2.114 873.4 274.3 132 24.96
Enterprise Value (EV) 1 11.65 3.724 836 233.8 117.1 13.36
P/E ratio -24.5 x -0.28 x -82.9 x -6.44 x -2.5 x -0.24 x
Yield - - - - - -
Capitalization / Revenue 19.2 x - - 82.6 x 21.7 x 3.94 x
EV / Revenue 20.6 x - - 70.4 x 19.3 x 2.11 x
EV / EBITDA -24.1 x -3.94 x -43.2 x -7.22 x -3.69 x -0.82 x
EV / FCF -21.8 x -6.83 x -56.2 x -10.9 x -6.11 x -3.47 x
FCF Yield -4.59% -14.7% -1.78% -9.15% -16.4% -28.8%
Price to Book 0.51 x 0.15 x 13 x 1.41 x 0.91 x 0.47 x
Nbr of stocks (in thousands) 5,222 5,285 8,117 11,026 10,997 12,540
Reference price 2 2.080 0.4000 107.6 24.88 12.00 1.990
Announcement Date 4/30/19 4/30/20 4/15/21 4/1/22 4/14/23 4/30/24
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.565 - - 3.321 6.081 6.328
EBITDA 1 -0.483 -0.946 -19.36 -32.38 -31.74 -16.21
EBIT 1 -0.5 -0.947 -19.36 -34.24 -35.21 -19.53
Operating Margin -88.5% - - -1,030.89% -578.98% -308.64%
Earnings before Tax (EBT) 1 -0.416 -12.16 -6.261 -35.52 -54.32 -111.7
Net income 1 -0.436 -7.46 -7.828 -34.7 -50.79 -98.18
Net margin -77.17% - - -1,045.02% -835.22% -1,551.53%
EPS 2 -0.0851 -1.418 -1.298 -3.864 -4.805 -8.354
Free Cash Flow 1 -0.535 -0.5456 -14.87 -21.39 -19.15 -3.849
FCF margin -94.69% - - -644.23% -314.94% -60.82%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/30/19 4/30/20 4/15/21 4/1/22 4/14/23 4/30/24
1CHF in Million2CHF
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 0.79 1.61 - - - -
Net Cash position 1 - - 37.4 40.5 14.9 11.6
Leverage (Debt/EBITDA) -1.631 x -1.702 x - - - -
Free Cash Flow 1 -0.54 -0.55 -14.9 -21.4 -19.2 -3.85
ROE (net income / shareholders' equity) -2.06% -41.9% -19.2% -27.9% -31.1% -99.4%
ROA (Net income/ Total Assets) -0.94% -2.14% -24.7% -13% -9.99% -9.21%
Assets 1 46.43 349.4 31.67 267.3 508.3 1,066
Book Value Per Share 2 4.080 2.710 8.260 17.70 13.20 4.200
Cash Flow per Share 2 0.0500 0.0200 4.690 4.350 1.750 1.170
Capex - - - - 0.03 0.45
Capex / Sales - - - - 0.54% 7.05%
Announcement Date 4/30/19 4/30/20 4/15/21 4/1/22 4/14/23 4/30/24
1CHF in Million2CHF
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.86B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.66B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. RLF Stock
  4. RLFTY Stock
  5. Financials Relief Therapeutics Holding SA